podcast

R&D

Biotech trends in COVID era: the pharmaphorum podcast

In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical compa

R&D

pharmaphorum_podcast-Episode-25-1200x675

GSK and eosinophil research: the pharmaphorum podcast

GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).

Sales & Marketing

Gitte Aabo on telemedicine and GN Hearing: the pharmaphorum ...

Joining the pharmaphorum podcast for episode 24 is Gitte Aabo, who last year moved to hearing aid technology firm GN Hearing as CEO.

R&D

The Alderley Park Discovery Podcast: COVID testing and the L...

Alderley Park’s Mereside campus is at the forefront of the UK’s COVID-19 testing plans, playing a key role in the national Lighthouse Lab programme.

R&D

Alnylam, gene-silencing and biotech in 2020: the pharmaphoru...

Alnylam's Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company's work in gene-silencing and how it could offer a route to target the current coronavirus p

Podcasts

Novartis, company culture and COVID-19: the pharmaphorum pod...

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future.